VVM
APRE icon

Versant Venture Management’s Aprea Therapeutics APRE Stock Holding History

Versant Venture Management’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-62,983
Closed -$6.44M – 11
2021
Q3 		$6.44M Hold
62,983
– – 2.67% 8
2021
Q2 		$6.15M Hold
62,983
– – 2.04% 9
2021
Q1 		$6.42M Sell
62,983
-8,333
-12% -$972K 1.25% 9
2020
Q4 		$7.02M Sell
71,316
-21,395
-23% -$10.2M 0.73% 10
2020
Q3 		$44.6M Hold
92,711
– – 8.17% 3
2020
Q2 		$71.9M Buy
+92,711
New +$60.8M 10.33% 3

Other funds holding APRE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return

Versant Venture Management's APRE Position: Q4 2021 in Review

Versant Venture Management sold out of Aprea Therapeutics (APRE) in Q4 2021, closing a stake of 62,983 shares — an estimated $6.44M sold.

Versant Venture Management first reported a position in APRE in Q2 2020 and held it in 6 quarters. The position peaked at $71.9M in Q2 2020. 41 funds tracked by Wall St. Rank hold APRE as of Q4 2021.

  • Versant Venture Management reported no remaining Aprea Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Versant Venture Management sold 62,983 Aprea Therapeutics shares in Q4 2021, an estimated $6.44M.
  • Versant Venture Management first reported a position in Aprea Therapeutics in Q2 2020 and held it in 6 quarters.
  • Versant Venture Management's Aprea Therapeutics position peaked at $71.9M in Q2 2020.
  • 41 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q4 2021.

Based on Versant Venture Management's 13F filing for Q4 2021, filed 11 Feb 2022.